Areas of Interest
Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, neurodegenerative disease occurred in central nervous system. Based on the report of National Institutes of Health (NIH), a total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist. The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons/year, and the mean age of diagnosis is 32 years. Females are twice as likely to live with MS as males. Currently existing drugs still need improvements for more efficacy and less side effects.
Cancers
According to National Institutes of Health (NIH), by 2050, 35.3 million cancer cases worldwide are expected, a 76.6% increase from the 2022 estimate of 20 million. Similarly, 18.5 million cancer deaths are projected by 2050, an 89.7% increase from the 2022 estimate of 9.7 million. Cancer cases and deaths are projected to nearly triple in low-HDI (Human Development Index) countries by 2050, compared to a moderate increase in very high–HDI countries (142.1% vs 41.7% for cancer cases and 146.1% vs 56.8% for cancer deaths). To treat this category of diseases, developing immune-modulating drugs is one of our approaches.
Alzheimer’s Disease
The report from NIH (National Institutes of Health) stated that an estimated 6.9 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060, barring the development of medical breakthroughs to prevent or cure AD (Alzheimer's disease). Official AD death certificates recorded 119,399 deaths from AD in 2021. For global review, there were over 55 million people worldwide with dementia in 2020. The number will be reaching 78 million and 139 million in 2030 and 2050, respectively. Still no completely effective treatments exist for this disease.
Parkinson’s Disease
From the National Institutes of Health (NIH), Parkinson's disease (PD) is the second-most common neurodegenerative disorder in the United States. Most people diagnosed with PD are age 60 years or older, however, an estimated 5 to 10 percent of people with PD are diagnosed before the age of 50. Approximately 500,000 Americans are diagnosed with PD, but given that many individuals go undiagnosed or are misdiagnosed the actual number is likely much higher. Some experts estimate that as many as 1 million Americans have PD. From World Health Organization (WHO), the prevalence of PD has globally doubled in the past 25 years with estimates in 2019 showing over 8.5 million individuals living with PD. Disability and death due to PD are increasing faster than any other neurological disorder. Current estimates suggest that, in 2019, PD resulted in 5.8 million disability-adjusted life years, an increase of 81% since 2000. It caused 329,000 deaths, an increase of over 100% since 2000. Only partially effective drugs are available for this disease.